Godal H C, Ly B
Scand J Haematol. 1977 Nov;19(5):443-8. doi: 10.1111/j.1600-0609.1977.tb01499.x.
An inhibitor of fibrin cross-linking was studied. The inhibitor was quantitatively separated together with the IgG fraction of plasma, but attempts to neutralize the purified inhibitor by commercial anti-IgG sera gave inconstant results, possibly due to anti-factor XIII activity demonstrable in these sera. The inhibitor prevented cross-linking by activated factor XIII, even when tested on preformed fibrin, but was inactive when assayed by the use of a synthetic substrate (monodansylcadaverine). Since, the inhibitor remained in the supernatant after defibrination, and was thus not associated with clottable proteins, the present findings suggest inhibition of activated f. XIII and not blockade of cross-linking sites on fibrinogen.
对一种纤维蛋白交联抑制剂进行了研究。该抑制剂与血浆的IgG组分一起被定量分离,但用市售抗IgG血清中和纯化后的抑制剂时,结果并不稳定,这可能是由于这些血清中可检测到抗因子XIII活性。该抑制剂可阻止活化因子XIII介导的交联,即使在预先形成的纤维蛋白上进行测试时也是如此,但在用合成底物(单丹磺酰尸胺)检测时则无活性。由于该抑制剂在纤维蛋白原溶解后仍留在上清液中,因此不与可凝固蛋白相关,目前的研究结果表明其抑制的是活化的因子XIII,而非纤维蛋白原上的交联位点。